CN118647381A - 治疗心血管病状的方法和提高心脏代谢效率的方法 - Google Patents

治疗心血管病状的方法和提高心脏代谢效率的方法 Download PDF

Info

Publication number
CN118647381A
CN118647381A CN202280085857.0A CN202280085857A CN118647381A CN 118647381 A CN118647381 A CN 118647381A CN 202280085857 A CN202280085857 A CN 202280085857A CN 118647381 A CN118647381 A CN 118647381A
Authority
CN
China
Prior art keywords
imb
dose
subjects
trimetazidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280085857.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·帕特尔
P·钱伯林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambria Pharmaceutical
Original Assignee
Ambria Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambria Pharmaceutical filed Critical Ambria Pharmaceutical
Publication of CN118647381A publication Critical patent/CN118647381A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202280085857.0A 2021-11-01 2022-10-31 治疗心血管病状的方法和提高心脏代谢效率的方法 Pending CN118647381A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274389P 2021-11-01 2021-11-01
US63/274,389 2021-11-01
PCT/US2022/048401 WO2023076665A1 (en) 2021-11-01 2022-10-31 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism

Publications (1)

Publication Number Publication Date
CN118647381A true CN118647381A (zh) 2024-09-13

Family

ID=86158627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280085857.0A Pending CN118647381A (zh) 2021-11-01 2022-10-31 治疗心血管病状的方法和提高心脏代谢效率的方法

Country Status (9)

Country Link
US (1) US20250235447A1 (https=)
EP (1) EP4426301A4 (https=)
JP (1) JP2024540172A (https=)
KR (1) KR20240095326A (https=)
CN (1) CN118647381A (https=)
AU (1) AU2022376557A1 (https=)
CA (1) CA3236328A1 (https=)
IL (1) IL312523A (https=)
WO (1) WO2023076665A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054580A1 (en) * 2023-09-08 2025-03-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
TWI683808B (zh) * 2017-07-18 2020-02-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有胺或(硫)醯胺之lxr調節劑
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Also Published As

Publication number Publication date
US20250235447A1 (en) 2025-07-24
WO2023076665A1 (en) 2023-05-04
EP4426301A1 (en) 2024-09-11
JP2024540172A (ja) 2024-10-31
AU2022376557A1 (en) 2024-05-02
CA3236328A1 (en) 2023-05-04
KR20240095326A (ko) 2024-06-25
IL312523A (en) 2024-07-01
EP4426301A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
Skyrme-Jones et al. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study
Anton et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study
JP2018184463A (ja) スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
Kumar et al. Diabetes epidemic in India—a comprehensive review of clinical features, management and remedies
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
WO2007106792A2 (en) Methods for treating sarcopenia with a growth hormone secretagogue
Strugaru et al. Metformin induced lactic acidosis–particularities and course
CN118647381A (zh) 治疗心血管病状的方法和提高心脏代谢效率的方法
Guthrie et al. Management of diabetes mellitus: a guide to the pattern approach
Baranowski et al. Effect of exogenous β-hydroxybutyrate on BDNF signaling, cognition, and amyloid precursor protein processing in humans with T2D and insulin-resistant rodents
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
Amery et al. Antihypertensive therapy in elderly patients: Pilot trial of the European Working Party on high blood pressure in the elderly
TW201904584A (zh) 減少或預防第ｉｉ型糖尿病患者中心血管事件之方法
Hap et al. Phenotypic risk factors for new-onset diabetes mellitus (NODAT) in renal transplant recipients.
Dwivedi et al. Beta-thalassemia, hyperlipoproteinemia (a), and metabolic syndrome: its low-cost holistic therapy
Licata et al. Obesity and cardiovascular diseases
Ansari et al. Effectiveness of fenugreek for lowering hemoglobin (HbA1c) in patients with self-management of type 2 diabetes: a randomized, controlled trial
REDDY et al. EFFECT OF PREOPERATIVE ORAL CARBOHYDRATE LOADING ON INTRAOPERATIVE BLOOD GLUCOSE LEVELS AND POSTOPERATIVE NAUSEA AND VOMITING
Extremera et al. Clinical Trials on Diabetes Mellitus
Baranowski et al. Effect of exogenous β-hydroxybutyrate on BDNF signalling, cognition, and amyloid 1 precursor protein processing in humans with T2D and insulin resistant rodents 2 3 4
HK40110115A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Melekhovets Diabetes Mellitus Management. Practical Guide with Elements of Augmented Reality
RU2554806C1 (ru) Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа
ELGHERDAWI et al. EFFICACY AND SAFTEY OF METFORMIN AND COMBINATION THERAPY OF INSULIN AND METFORMIN IN TYPE 2 DIABETIC PATIENTS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination